Results 101 to 110 of about 4,266 (228)

Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB

JIMD Reports, Volume 67, Issue 3, May 2026.
ABSTRACT Mucopolysaccharidosis Type IV is a multisystem lysosomal storage disease characterized by severe skeletal dysplasia resulting from impaired degradation of the glycosaminoglycans keratan sulfate and chondroitin‐6‐sulfate. The condition is classified into Types A and B based on the underlying enzyme deficiency.
Mark Wijnen, Evert F. S. van Velsen, J. Gert‐Jan Milhous, Esmee Oussoren, Bram C. J. van der Eerden, Margreet A. E. M. Wagenmakers   +5 more
wiley   +1 more source

Cardiovascular Safety of Romosozumab Compared to Commonly Used Anti-osteoporosis Medications in Postmenopausal Osteoporosis: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials

Drug Safety
The aim of this study was to investigate the cardiovascular safety of romosozumab in postmenopausal women with osteoporosis. Romosozumab, a monoclonal antibody targeting sclerostin, has been shown to increase bone mineral density and reduce the risk of ...
Shih-Hao Cheng, William C. Chu, Wen-Hsiang Chou, W. Chu, Y. Kang   +4 more
semanticscholar   +1 more source

Comparison of Denosumab with Romosozumab in the treatment of male osteoporosis: a retrospective cohort study

Scientific Reports
We aimed to investigate the efficacy of romosozumab treatment compared with that of denosumab in especially male osteoporosis patients. This retrospective cohort study included 174 Japanese male patients receiving either denosumab or romosozumab for 12 ...
Tomonori Kobayakawa, Yasuhide Kanayama, Yuji Hirano, Yukio Nakamura   +3 more
doaj   +1 more source

The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis.

Journal of Clinical Endocrinology and Metabolism
PURPOSE The purpose of this observational study was to investigate the effectiveness and safety of romosozumab (ROMO) and teriparatide (TPTD) in a clinical setting.
M. Hartz, Fabian B Johannessen, T. Harsløf, B. Langdahl   +3 more
semanticscholar   +1 more source

3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate

Romosozumab treatment in women with postmenopausal osteoporosis increases bone formation while decreasing bone resorption, resulting in large BMD gains to reduce fracture risk within 1 year.
Ferrari, Serge Livio, Betah, Donald, Oates, Mary, Lewiecki, E Michael, Omura, Fumitoshi, Humbert, Ludovic, Libanati, Cesar, Shi, Yifei, Winzenrieth, Renaud   +8 more
core   +1 more source

Atypical femur fracture following romosozumab and bisphosphonate treatment

Romosozumab, a monoclonal antibody against sclerostin, is a newly licensed dual-acting osteoporosis treatment for patients at very high risk of fracture.
Jacunski, Mark, Hauser, Barbara, Johnsson, Hanna, Ralston, Stuart H   +3 more
core   +1 more source

Romosozumab: from basic to clinical aspects [PDF]

Expert Opinion on Biological Therapy, 2014
The Wnt pathway has an important role in bone formation. Inactivation of sclerostin, an inhibitor of this pathway, has been associated with increased bone mass both in animal experiments and in human clinical trials. Romosozumab is a humanized monoclonal antibody targeting sclerostin.
openaire   +3 more sources

Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study

, 2016
Romosozumab is a humanized immunoglobulin G2 monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling.
Ominsky, Michael S., Samadfam, Rana, Smith, Susan Y., Felx, Melanie, Boyce, Rogely Waite, Buntich, Sabina, Locher, Kathrin, Mann, Peter, Chouinard, Luc, Pyrah, Ian, Varela, Aurora, Jolette, Jacquelin, Mellal, Nacera   +12 more
core   +1 more source

A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis

Scientific Reports
We compared the efficacy of romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis in a randomized controlled trial.
Yasumori Sobue, Hironobu Kosugiyama, Shuji Asai, Yoshikazu Ogawa, Minoru Yoneda, Koji Maruyama, Mariko Kaneko, Tomonori Kobayakawa, Kenya Terabe, Mochihito Suzuki, Ryo Sato, Yusuke Ohno, Junya Hasegawa, Takaya Sugiura, Masahiko Ando, Yachiyo Kuwatsuka, Naoki Ishiguro, Shiro Imagama   +17 more
doaj   +1 more source

Wnt/β-catenin pathway as a potential target for Parkinson’s disease: a cohort study of romosozumab using routinely collected health data in Japan

Frontiers in Pharmacology
IntroductionRomosozumab is a monoclonal antibody approved for osteoporosis which targets sclerostin, an endogenous inhibitor of Wnt/β-catenin pathway. Given the essential roles of the Wnt/β-catenin pathway in various tissues, we hypothesized romosozumab ...
Shoichiro Inokuchi, Koji Shimamoto
doaj   +1 more source